Colorectal cancer (CRC) is a major public health problem in Indonesia. It ranks among the top four cancers with high mortality rates. CRC screening is expected to improve early diagnosis that can reduce mortality and morbidity rate. Primary health care-based CRC screening in Indonesia has not yet been performed. This study was conducted to obtain information about prevalence, adenoma detection rate and public compliance for CRC screening in Semarang, Indonesia. This cross-sectional study was done across 10 primary health care centers in Semarang during April—October 2021. The screening method used Immunochromatography Faecal Occult Blood Tests (I-FOBT) as the primary test. Patients with positive I-FOBT result would be referred to Kariadi hospital for colonoscopy and histology examination. A total of 221 patients were included, 66.1% were female, mean age was 59.38 ± 7.48 years. Participation rate was 63%, 37 patients (16.7%) were I-FOBT positive, 26 patients (70.27%) underwent colonoscopy. Colonoscopy compliance rate was 70.27%. The colonoscopy results were haemorrhoid (30.8%), polyps (30.8%), malignancy (19.2%), colitis (7.7%), diverticulosis (7.7%), and normal (3.8%). The adenoma detection rate was 26.9%. BMI abnormality (overweight and obese) (OR 10.968; 95% CI 2.33–51.55) and family history of malignancy (OR 18.800; 95% CI 5.13–68.85) increased the risk of colorectal cancer and adenoma and respectively. The prevalence of I-FOBT positive in primary health care centers is high. The CRC screening program based on primary care should be considered. Public awareness education should be considered to increase colonoscopy compliance.
Colorectal cancer (CRC) continues to be a primary contributor to the global health burden, and early detection is vital for optimal outcomes. Standard detection techniques, including colonoscopy and fecal occult blood tests, have been confirmed effective yet their invasiveness and poor sensitivity are a limitation. MicroRNA (miRNA) are now recognized as stable non-invasive biomarkers with differential expression in cancerous tissues, but reports have been heterogeneous and studied under different settings. This study, completed based on PRISMA guidelines, was a systematic review of miRNA signature diagnostic accuracy to detect early CRC. Case-case control studies, cross-sectional, and cohort research published between 2014–2024 were identified through the Scopus, PubMed, and Cochrane databases. We extracted diagnostic metrics such as sensitivity and specificity while assessing bias with the ROBINS-e tool and the Newcastle-Ottawa Scale. Meta-analyses showed that miRNA panels have high diagnostic accuracy with a pooled sensitivity of 1.84 (95% CI: 1.48–2.19) and a pooled specificity of 1.43 (95% CI: 1.01–1.85). The accuracy of miRNA-139-3p was the highest among all panels. Meta-regression did not reveal any significant confounders, while publication bias was not detected. These results highlight the miRNA panels’ potential as non-invasive biomarkers in early CRC detection, providing a promising alternative to conventional screening methods, with miRNA-139-3p as the most diagnostically accurate biomarker.
15 December 2022 in Journal of Biomedicine and Translational Research
Background: Stress-related mucosal disease (SRMD) frequently develops in critically ill patients, increasing mortality and length of intensive care unit (ICU) stay. There is limited data on stress ulcer prophylaxis (SUP) on critically ill patients in Indonesia. Objective:Methods: This is a retrospective cohort study of patients admitted to the ICU from January 1, 2015, to December 31, 2017. The subjects were all ICU patients who used proton pump inhibitor (PPI) and histamine-2 receptor antagonist (H2RA) as SUP therapy.Results: A total of 315 patients were included, and mean age was 48 years. Approximately 55.2% were women, and 62.8% of patients were admitted to ICU following high-risk surgery. PPI was given to 187 patients (59.4%) and H2RA to 128 patients (40.6%), with an average usage for 5 days. The incidence of SRMD was 15.9% (n = 50), and mean length of stay in the ICU was 6 days. Gender, age, duration of SUP, and ICU length of stay of the PPI and H2RA groups were not statistically different (p > 0.05) and did not affect the GI event (p > 0.05). The use of rational SUP was 98.4%. Major American Society of Health-System Pharmacists (ASHP) risk factor criterion was ventilator use (86.8%), while the minor ASHP criterion was anticoagulant therapy (22.2%). The incidence of GI event was significantly lower in PPI groups than H2RA groups (p < 0.05). Conclusions: The use of SUP is rational with an average use of 5 days. PPI are superior to H2RA for SRMD prophylaxis.